

Profiles
April 16, 2015

LIST OF PUBLICATIONS

Guy Chouinard

1. Bordeleau JM, Chouinard G, Tétreault L: Étude des propriétés hypnotiques d'une nouvelle benzodiazépine, le mogadon. *Union Med Can* 95: 45-50, 1966.
- +2. Chouinard G, Ban TA, Lehmann HE, Ananth JV: Fluspirilene in the treatment of chronic schizophrenic patients. *Curr Ther Res* 12: 604-608, 1970.
3. Chouinard G, Lehmann HE, Ban TA: Pimozide in the treatment of chronic schizophrenic patients. *Curr Ther Res* 12:598-603, 1970.
4. Chouinard G, Pinard G, Prenoveau Y, Tetreault L: Alpha methyl-dopa-chlorpromazine interaction in schizophrenic patients. *Curr Ther Res* 15:60-72, 1973.
5. Chouinard G, Ananth JV, Ban TA, Lehmann HE: Diphenylbutylpiperidines in the treatment of chronic schizophrenic patients. In: *Les Diphenylbutylpipéridines*, edited by A. Villeneuve, J.-M. Bordeleau. Québec Psychopharmacological Research Association, Les Presses de l'Université Laval, Québec, pp. 56-65, 1973.
6. Chouinard G, Pinard G, Serrano M, Tetreault L: Potentiation of haloperidol by alphanethyl-dopa in the treatment of schizophrenic patients. *Curr Ther Res* 15:473-483, 1973.
7. Chouinard G: Étude de l'association chlorpromazine-alphanéthyl-dopa chez le schizophrène. Thèse, Maîtrise en Sciences (Pharmacologie). Université de Montréal, février, 1974.
8. Chouinard G, Annable L, Mélançon J, Chabot M: Chlorpromazine-induced electrocardiogram abnormalities. *Int J Clin Pharmacol* 11:327-331, 1975.
9. Chouinard G, Annable L, Dubrovsky B, Dongier M: Post-imperative negative variation (PINV) in ambulatory schizophrenic patients. *Compr Psychiatry* 16:457-460, 1975.
10. Chouinard G: Psychopharmacology in the elderly. *Mod Med of Canada* 30:127-128, 1975.
11. Chouinard G: Pharmacotherapy and general management of depression. *Mod Med of Canada* 30:349-352, 1975.
12. Chouinard G, Annable L, Serrano M, Albert J-M, Charette R: Amitriptyline-

- perphenazine interaction in ambulatory schizophrenic patients. *Arch Gen Psychiatry* 32: 1295-1307, 1975.
13. Chouinard G: Schizophrénie et catécholamines. *Union Med Can* 104:885-889, 1975.
 14. Chouinard G: Emploi du carbonate de lithium en psychiatrie. In: *Cahier Pédagogique II. La Problématique du Lithium*, edited by C. Laurin. Département de Psychiatrie, Faculté de Médecine, Université de Montréal, pp. 80-85, June, 1975.
 15. Chouinard G, Fontaine R: Fluphenazine with other antipsychotic drugs (ltr to ed) *Am J Psychiatry* 132:760-761, 1975.
 16. Chouinard G, Annable L: Penfluridol in the treatment of newly admitted schizophrenic patients in a brief therapy unit. *Am J Psychiatry* 133:820-823, 1976.
 17. Chouinard G, Annable L: Clozapine in the treatment of newly admitted schizophrenic patients: A pilot study. *J Clin Pharmacol* 16:289-297, 1976.
 18. Chouinard G: Guide pratique pour l'emploi des agents psychopharmacologiques. I. Emploi de carbonate de lithium. *Union Med Can* 105:779-784, 1976.
 19. Chouinard G: More on fluphenazine and polypharmacy - Reply. (Letter to editor). *Am J Psychiatry* 133:105-106, 1976.
 20. Chouinard G: Reducing oral medication with depot fluphenazine - Reply. (Letter to Editor). *Am J Psychiatry* 133:585-586, 1976.
 21. Chouinard G: Guide pratique pour l'emploi des agents psychopharmacologiques. II. Antipsychotiques et antiparkinsoniens. *Union Med Can* 105:1387-1397, 1976.
 22. Chouinard G, Annable L: Alphamethyldopa-chlorpromazine combination in schizophrenic patients. *Neuropsychobiology* 2:118-126, 1976.
 23. Chouinard G, Annable L, de Montigny C, Kropsky M: Loxapine succinate in the treatment of newly admitted schizophrenic patients. *Curr Ther Res* 21:73-79, 1977.
 24. Chouinard G, Annable L, Dongier M: Differences in psychopathology of schizophrenic patients with normal and abnormal post-imperative negative variation (PINV). *Compr Psychiatry* 18:83-87, 1977.
 25. Chouinard G, Young SN, Annable L, and Sourkes TL: Tryptophan-nicotinamide in depression. (Letter to Editor). *Lancet* I:249, 1977.
 26. Chouinard G, Annable L, Serrano M, Charette R: A controlled study of a dopa decarboxylase inhibitor (benserazide) in the treatment of schizophrenic patients. *Int Pharmacopsychiatry* 12:1-8, 1977.
 27. Chouinard G, Annable L: The effect of a glucose load on phenothiazine-induced electrocardiographic abnormalities. *Arch Gen Psychiatry* 34:951-954, 1977.

28. Chouinard G, Annable L, Kolivakis TNL: Penfluridol in the maintenance treatment of schizophrenic patients newly discharged from a brief therapy unit. *J Clin Pharmacol* 17:162-167, 1977.
29. Chouinard G, Annable L: Rubidium chloride in the treatment of schizophrenia. *Communications in Psychopharmacology* 1:373-383, 1977.
30. Chouinard G, Annable L, Cooper S: Antiparkinsonian drug administration and plasma levels of penfluridol, a new long-acting neuroleptic. *Communications in Psychopharmacology* 1:325-331, 1977.
31. Chouinard G: La thérapie électro-convulsive dans le traitement de la dépression. *Union Med Can* 106:817-820, 1977.
32. Chouinard G: Guide pratique pour l'emploi des agents psychopharmacologiques: III. Antidépresseurs. *Union Med Can* 106:821-828, 1977.
33. Chouinard G, Annable L, Kropsky M: A double-blind controlled study of pipothiazine palmitate in the maintenance treatment of schizophrenic patients. *J Clin Pharmacol* 18:148-154, 1978.
34. Chouinard G, Annable L, Ross-Chouinard A: A double-blind controlled study of fluphenazine decanoate and enanthate in the maintenance treatment of schizophrenic outpatients. In: *Depot Fluphenazines: Twelve Years of Experience*, edited by F.J. Ayd, Jr., Baltimore, Ayd Medical Communications, pp. 111-123, 1978.
35. Chouinard G, Young SN, Annable L, Sourkes TL: Tryptophan dosage critical for its antidepressant effect (ltr to ed). *Br Med J* 1:1422, 1978.
36. Chouinard G, Annable L, Young SN, Sourkes TL: Tryptophan-benserazide in the treatment of schizophrenia. *Communications in Psychopharmacology* 2:21-31, 1978.
37. Chouinard G: Book Review: *Biological Foundations of Psychiatry, Volumes 1 & 2*. *Can Psychiatr Assoc J* 23:124-125, 1978.
38. Lesage J, Chouinard G: A case report of manic-depressive illness associated with Klinefelter's syndrome and essential tremors. Father-to-son transmission (ltr to ed). *Am J Psychiatry* 135:757-758, 1978.
39. Chouinard G: Les psychotropes en gériatrie. *Le Médecin du Québec* 13:90-91, 1978.
40. Chouinard G, Jones BD: Schizophrenia as dopamine-deficiency disease. *Lancet* II:99-100, 1978.
41. Chouinard G, Ghadirian AM, Jones BD: Death attributed to ventricular arrhythmia induced by thioridazine in combination with a single Contac-C capsule. *Can Med Assoc J*

- 119:729-731, 1978.
42. Chouinard G, Jones BD, Annable L: Neuroleptic-induced supersensitivity psychosis. *Am J Psychiatry* 135:1409-1410, 1978.
 43. Chouinard G, Young SN, Annable L, Sourkes TL: Tryptophan-nicotinamide in the treatment of newly admitted depressed patients. *Communications in Psychopharmacology* 2:311-318, 1978.
 44. Chouinard G, Jones BD: Drug interaction studies in the support of schizophrenia as dopamine deficiency disease. *Proceedings of the Founding Meeting of the Canadian College of Neuropsychopharmacology*, edited by D.J. McClure, Montreal, pp.125-144, 1978.
 45. Chouinard G, Annable L, Ross-Chouinard A, Kropsky M: Ethopropazine and benztropine in neuroleptic-induced parkinsonism. *J Clin Psychiatry* 40:73-80, 1979.
 46. Chouinard G, Annable L, Ross-Chouinard A, Nestoros JN: Factors related to tardive dyskinesia. *Am J Psychiatry* 136:79-83, 1979.
 47. Chouinard G, Young SN, Annable L, Sourkes TL: Tryptophan-nicotinamide, imipramine and their combination in depression. *Acta Psychiatr Scand* 59:395-418, 1979.
 48. Chouinard G: Book Review: *Annales de Therapeutique Psychiatrique*, Vol. 5, par Henri Baruk. Paris: Presses Universitaires de France, 382, pp., 1974. *Can Psychiatr Assoc J* 24:94, 1979.
 49. Lesage J, Chouinard G: Sex chromosome anomalies and manic-depressive illness. Reply. (ltr to ed) *Am J Psychiatry* 136:240, 1979.
 50. Chouinard G, Jones BD, Young SN, Annable L: Potentiation of lithium by tryptophan in a patient with bipolar illness. *Am J Psychiatry* 136:719-720, 1979.
 51. Chouinard G, Jones BD: Death attributed to ventricular arrhythmia (ltr to ed). *Can Med Assoc J* 120:1058-1060, 1979.
 52. Chouinard G, Annable L, Ross-Chouinard A: Facteurs reliés à la dyskinésie tardive. *Union Med Can* 108:356-373, 1979.
 53. Chouinard G, Jones BD: Early onset of tardive dyskinesia: a case report. *Am J Psychiatry* 136:1323-24, 1979.
 54. de Montigny C, Chouinard G Annable L: Ineffectiveness of deanol in tardive dyskinesia: a placebo controlled study. *Psychopharmacology* 65:219-223, 1979.
 55. Chouinard G, Jones BD: Evidence of brain dopamine deficiency in schizophrenia. *Can J Psychiatr* 24:661-667, 1979.
 56. Chouinard G, de Montigny C, Annable L: Tardive dyskinesia and antiparkinsonian

medication. *Am J Psychiatr* 136:228-229, 1979.

57. Chouinard G, Jones BD: Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics. *Am J Psychiatr* 137:16-21, 1980.

58. Chouinard G, Jones BD, Annable L: Neuroleptic-induced supersensitivity psychosis. In: Phenothiazines and Structurally Related Drugs: Basic and Clinical Studies, Developments in Neuroscience Volume 7, edited by E. Usdin, H. Eckert and I.S. Forrest, New York Elsevier North Holland, 1980.
59. Chouinard G: Mise au point sur l'emploi du carbonate de lithium et les atteintes rénales et thyroïdiennes qui en découlent. *Union Med Can* 109:221-226, 1980.
60. Chouinard G, Annable L, Jones BD, Ross-Chouinard A: Sex differences and tardive dyskinesia (ltr to ed). *Am J Psychiatr* 137:507, 1980.
61. Chouinard G, Jones BD: Defining drug-induced supersensitivity (ltr to ed). *Am J Psychiatry* 137:992-993, 1980.
62. Chouinard G, Denis JF: Anxiolytiques et hypnotiques. In: *Manuel de Psychiatrie Clinique: Approche Contemporaine*, edited by P. Lalonde and F. Grunberg, Chicoutimi (Québec), Gaétan Morin & Associés Ltée, pp. 703-721, 1980.
63. Chouinard G, Denis JF: Les neuroleptiques. In: *Manuel de Psychiatrie Clinique. Approche Contemporaine*, edited by P. Lalonde and F. Grunberg, Chicoutimi (Québec), Gaétan Morin & Associés Ltée, pp. 723-741, 1980.
64. Chouinard G, Denis JF: Les antidépresseurs. In: *Manuel de Psychiatrie Clinique: Approche Contemporaine*, edited by P. Lalonde and F. Grunberg, Chicoutimi (Québec), Gaétan Morin & Associés Ltée, pp. 743-753, 1980.
65. Chouinard G, Denis JF: Le lithium. In: *Manuel de Psychiatrie Clinique: Approche Contemporaine*, edited by P. Lalonde and F. Grunberg, Chicoutimi (Québec), Gaétan Morin & Associés Ltée, pp. 755-766, 1980.
66. Chouinard G, La sismothérapie, thérapie électroconvulsive. In: *Manuel de Psychiatrie Clinique: Approche Contemporaine*, edited by P. Lalonde and F. Grunberg, Chicoutimi (Québec), Gaétan Morin & Associés Ltée, pp. 767-775, 1980.
67. Chouinard G, Jones BD: Anticholinergics and tardive dyskinesia. - Reply. (Letter to Editor). *Am J Psychiatry* 137:1470-1471, 1980.
68. Chouinard G, Annable L, Olivier M, Fontaine F, Ross-Chouinard A: Psychotropic and neuropsychologic effects of piracetam in geriatric psychiatric patients: a controlled study. In "Proceedings of International Symposium on Nootropic Drugs", Rio de Janeiro, Brazil, pp. 23-30, 1980.
69. Young SN, Chouinard G, Annable L: Tryptophan in the treatment of depression. In "Serotonin: Current Aspects of Neurochemistry and Function", edited by B. Haber, S. Gabay, M.R. Issidorides and SGA Alivisatos, New York, Plenum, pp. 727-737, 1981.

70. Boisvert D, Chouinard G: Perspectives psychopharmacologiques. *Le Médecin du Québec* 16:79-85, 1981.
71. Chouinard G: Book review: Haloperidol Update: 1958-1980. Ayd FJ (ed), Baltimore, Ayd Medical Communications, pp. 234, 1980. *Can J Psychiatry* 26(2):130-131, 1981.
72. Chouinard G, Boisvert D: Lithium and regression of oat-cell carcinoma. (Letter to Editor). *Can Med Assoc J* 124:1555, 1981.
73. Boisvert D, Chouinard G: Rebound cardiac arrhythmia after withdrawal from imipramine: a case report. *Am J Psychiatry* 138:985-986, 1981.
74. Chouinard G, Annable L, Jones BD, Collu R: Lack of tolerance to long-term neuroleptic treatment in dopamine tuberoinfundibular system. *Acta Psychiatr Scand* 64:353-362, 1981.
75. Chouinard G, Annable L, Langlois R: Absence of orthostatic hypotension in depressed patients treated with bupropion. *Prog Neuro-Psychopharmacol* 5:483-490, 1981.
76. Chouinard G, Annable L, Collu R: Plasma prolactin levels: a psychiatric tool. In: *Brain Peptides and Hormones*. Collu R, Ducharme JR, Tolis G, Barbeau A (eds), Raven Press, pp. 333-341, 1982.
77. Chouinard G, Annable L: Pimozide in the treatment of newly admitted schizophrenic patients. *Psychopharmacology* 76:13-19, 1982.
78. Chouinard G: Neuroleptic-induced supersensitivity psychosis. In: *Tardive Dyskinesia and Related Involuntary Movement Disorders: The Long-Term Effects of Antipsychotic Drugs*. DeVeugh-Geiss J (ED), John Wright PSG of Boston, Massachusetts, pp.109-115, 1982.
79. Chouinard G, Annable L, Ross-Chouinard A: Fluphenazine enanthate and fluphenazine decanoate in the treatment of schizophrenic outpatients: extrapyramidal symptoms and therapeutic effect. *Am J Psychiatry* 139:312-318, 1982.
80. Chouinard G, Bradwejn J: Reversible and irreversible tardive dyskinesia: a case report. *Am J Psychiatry* 139:3, 360-362, 1982.
81. Chouinard G, Boisvert D, Bradwejn J: Tardive dyskinesia in a non-psychiatric patient due to short-term use of a neuroleptic/anticholinergic combination drug. *Can Med Assoc J* 126:821-822, 1982.
82. Chouinard G, Creese I, Boisvert D, Annable L, Bradwejn J, Jones B: High Neuroleptic Plasma Levels in Patients Manifesting Supersensitivity Psychosis. *Biol Psychiatry* 17:849-852, 1982.
83. Young SN, Gauthier S, Chouinard G, Anderson GM, Purdy WC: The Effect of Carbidopa and Benzerazide on Human Plasma 5-Hydroxytryptophan Levels. *J Neural*

Transmission 53:83-87, 1982.

84. Chouinard G, Jones B: Neuroleptic-Induced Supersensitivity Psychosis, The 'Hump Course' and Tardive Dyskinesia. (Letter to Editor). *J Clin Psychopharmacology* 2:143-144, 1982.
85. Ghadirian AM, Chouinard G, Annable L: Sexual dysfunction and plasma prolactin levels in neuroleptic-treated schizophrenic outpatients. *J Nerv Ment Dis* 170:463-467, 1982.
86. Chouinard G, Annable L, Fontaine R, Solyom L: Alprazolam in the treatment of anxiety and panic disorders: A double-blind placebo-controlled study. *Psychopharmacology* 77:229-233, 1982.
87. Belanger MC, Chouinard G: Technique for injecting long-acting neuroleptics. (Letter to Editor). *Br J Psychiatry* 141:316, 1982.
88. Chouinard G, Steinberg S: Book review. *Clinical Psychiatry in Primary Care. Can Med Assoc J* 127:325, 1982.
89. Chouinard G, Steinberg S: Type I tardive dyskinesia induced by anticholinergic drugs, dopamine agonists and neuroleptics. *Prog Neuro-Psychopharmacol & Biol Psychiatr* 6:571-578, 1982.
90. Chouinard G, Young SN, Bradwejn J, Annable L: Tryptophan in the Treatment of Depression and Mania. In: *Adv Biol Psychiat Vol. 10*, pp. 47-66, Editors van Praag/Mendlewicz, Publisher S. Karger, Basel, 1983.
91. Chouinard G, Young SN, Annable L: Antimanic Effect of Clonazepam. *Biol Psychiatry* 18:451-466, 1983.
92. Chouinard G, Steinberg S: Schizophrenia. *Medicine North America J* 34:3172-3179, 1983.
93. Chouinard G: Supersensitivity Psychosis. *Hillside J Clin Psychiatry* 4:131-140, 1983.
94. Fontaine R, Annable L, Chouinard G, Ogilvie RI: Bromazepam and diazepam in generalized anxiety: a placebo-controlled study with measurement of drug plasma concentrations. *J Clin Psychopharmacol* 3:80-87, 1983.
95. Chouinard G, Annable L, Fontaine R, Solyom L: Alprazolam in the treatment of generalized anxiety and panic disorders: a double-blind placebo-controlled study. *Psychopharmacol Bull* 19:115-116, 1983.
96. Chouinard G, Annable L: Fluspirilene in the treatment of newly admitted schizophrenic patients. *Psychopharmacol Bull* 19:136-138, 1983.
97. Chouinard G, Annable L, Ross-Chouinard A, Olivier M, Fontaine F: Piracetam in elderly

- psychiatric patients with mild diffuse cerebral impairment. *Psychopharmacology* 81: 100-106, 1983.
98. Chouinard G: Bupropion and amitriptyline in the treatment of depressed patients. *J Clin Psychiatry* 44:121-129, 1983.
99. Mendels J, Amin MM, Chouinard G, Cooper AJ, Miles JE, Remick RA, Saxena B, Secunda SK, Singh AN: A comparative study of bupropion and amitriptyline in depressed outpatients. *J Clin Psychiatry* 44:118-120, 1983.
100. Chouinard G, Labonte A, Fontaine R, Annable L: New concepts in benzodiazepine therapy: rebound anxiety and new indications for the more potent benzodiazepines. *Prog Neuro Biol Psychiat* 7: 669-673, 1983.
101. Chouinard G, Steinberg S: New clinical concepts on neuroleptic-induced supersensitivity disorders: tardive dyskinesia and supersensitivity psychosis. In: *Guidelines for the Use of Psychotropic Drugs*. Edited by Stancer et al., S.P. Medical & Scientific Books, Spectrum Publications, Jamaica, N.Y., pp. 205-227, 1984.
102. Jones BD, Steinberg S, Chouinard G: Fast-cycling bipolar disorder induced by withdrawal from long-term treatment with a tricyclic antidepressant. *Am J Psychiatry* 141:1, 108-109, 1984.
103. Fontaine R, Chouinard G, Annable L: Rebound anxiety in anxious patients after abrupt withdrawal of benzodiazepine treatment. *Am J Psychiatry* 141:7, 848-852, 1984.
104. Chouinard G, Annable L, Bradwejn J: An early phase II clinical trial of tomoxetine (LY139603) in the treatment of newly admitted depressed patients. *Psychopharmacology* 83:126-128, 1984.
105. Fontaine R, Chouinard G: Antipanic effect of clonazepam. (Letter to Editor). *Am J Psychiatry* 141:149, 1984.
106. Fontaine R, Chouinard G, Annable L: Bromazepam and diazepam in generalized anxiety: a placebo-controlled study of efficacy and withdrawal. *Psychopharmacol Bull* 20: 126-127, 1984.
107. Chouinard G, Annable L, Campbell W, Boisvert D, Bradwejn J: A double-blind controlled clinical trial of haloperidol decanoate and fluphenazine decanoate in the maintenance treatment of schizophrenia. *Psychopharmacol Bull* 20: 108-109, 1984.
108. Beaudry P, Fontaine R, Chouinard G: Bromazepam, another high-potency benzodiazepine, for panic attacks. (Letter to Editor). *Am J Psychiatry* 141: 464-465, 1984.
109. Young SN, Chouinard G, Annable L, Morand C, Ervin FR: The therapeutic action of

- tryptophan in depression, mania and aggression. In: Progress in Tryptophan and Serotonin Research. Edited by Schlossberger HG, Kochen W, March/84 Linzen B, Steinhart H. Berlin, de Gruyter & Co, pp. 321-324, 1984.
110. Chouinard G: Benzodiazepine selection in clinical use. In: Benzodiazepine Therapy Today, Edited proceedings of a Canadian Symposium. Hollister L, Lapierre Y (eds). Communications Media for Education, Princeton Jct., N.J., pp. 9-12, 1984.
111. Chouinard G: New pharmacological concepts in the treatment of anxiety disorders. Editors' Commentary. In: Focus/Psychiatric Practice. Communications Media for Education, Princeton Jct., N.J.. Vol 2, No 4, 1984.
112. Chouinard G, Bradwejn J, Annable L, Jones BD, Ross-Chouinard A: Withdrawal symptoms after long-term treatment with low potency neuroleptics. J Clin Psychiatry 45:500-502, 1984.
113. Chouinard G, Annable L: An early Phase II clinical trial of BW234U in the treatment of acute schizophrenia in newly admitted patients. Psychopharmacology 84:282-284, 1984.
114. Chouinard G, Jones B: No cross-over of hypersensitivity reactions between zimelidine and fluoxetine. (ltr to ed) Can Med Assoc J 131:1190, 1984.
115. Goldbloom D, Chouinard G: Clonazepan in the treatment of neuroleptic-induced somnambulism. (Letter to Editor). Am J Psychiatry 141:1486, 1984.
116. Poiré-Salnavé F, Bélanger M-C, Chouinard G: Le lithium - troisième révolution dans l'histoire de la maladie psychiatrique. L'infirmière canadienne 11:30-33, 1984.
117. Judge G, Birrell M, Burke M, Chouinard G, Cipywnyk D, de Groot P, Johnson G, Martin G (Working-Group on Addiction Services): Addiction services in Hospitals. Guidelines for establishing standards for special services in hospitals. Report of the Sub-Committee on Special Services in Hospitals. National Health & Welfare, 1984.
118. Fogel P, Mamer OA, Chouinard G, Farrell P: Determination of plasma bupropion and its relationship to therapeutic effect. Biomed Mass Spectrom 11:629-632, 1984.
119. Chouinard G, Steinberg S: Schizophrenia. In: Readings in Psychiatry 3. Oxford: Medical Education Services, p. 1-5, 1984.
120. Chouinard G, Annable L, Bradwejn J, Labonte A, Jones B, Mercier P, Bélanger M-C: An early Phase II clinical trial with follow-up of Tomoxetine (LY139603) in the treatment of newly admitted depressed patients. Psychopharmacol Bull 21:73-76, 1985.
121. Fontaine R, Annable L, Beaudry P, Mercier P, Chouinard G: Efficacy and withdrawal of

- two potent benzodiazepines: bromazepam and lorazepam. *Psychopharmacol Bull* 21:91-92, 1985.
122. Fontaine R, Chouinard G, Iny L: An open clinical trial of zimeldine in the treatment of obsessive compulsive disorder. *Curr Ther Res* 37:326-332, 1985.
123. Jones B, Chouinard G: Clonazepam in the treatment of psychiatric symptoms associated with systemic lupus erythematosus. *Am J Psychiatry* 142: 354-355, 1985.
124. Chouinard G: A double-blind controlled clinical trial of fluoxetine and amitriptyline in the treatment of outpatients with major depressive disorder. *J Clin Psychiatry* 47:32-37, 1985.
125. Chouinard G, Annable L, Campbell W, Boisvert D, Bradwejn J: A double-blind controlled clinical trial of haloperidol decanoate and fluphenazine decanoate in the maintenance treatment of schizophrenia. *Proceedings of the VIIth World Congress of Psychiatry*, In *Psychiatry: The State of the Art*, Vol. 3. P. Pichot, P. Berner, R. Wolf, K. Thau (eds), Plenum Publishing Corp., pp. 759-761, 1985.
126. Chouinard G, Young SN, Annable L: A controlled clinical trial of L-tryptophan in acute mania. *Biol Psychiatry* 20:546-557, 1985.
127. Goldbloom D, Chouinard G: Schizophreniform psychosis associated with chronic industrial toluene exposure. *J Clin Psychiatry* 46:350-351, 1985.
128. Fontaine R, Chouinard G: Anti-obsessive compulsive effect of fluoxetine. (Letter to editor). *Am J Psychiatry* 142:989, 1985.
129. Steinberg S, Chouinard G: A case of mania associated with tomoxetine. (Letter to Editor). *Am J Psychiatry* 142:1517-1518, 1985.
130. Cohen BM, Waternaux C, Chouinard G, Sommer BR, Jones B: Plasma levels of neuroleptic in patients receiving depot fluphenazine. *J Clin Psychopharmacol* 5:328-332, 1985.
131. Chouinard G: Antimanic effects of clonazepam. *Psychosomatics (Supplement)* 26(12):7-12, 1985.
132. Fontaine R, Chouinard G: Fluoxetine in the treatment of obsessive compulsive disorder. *Prog Neuro-Psychopharmacol & Biol Psychiatr* 9:605-608, 1985.
133. Chouinard G, Turnier L, Kallai-Sanfaçon M-A: Remoxipride in schizophrenia: effects on plasma prolactin. *Prog Neuro-Psychopharmacol & Biol Psychiatr* 9:599-603, 1985.
134. Beaudry P, Fontaine R, Chouinard G, Annable L: An open clinical trial of clonazepam in the treatment of patients with recurrent panic attacks. *Prog Neuro-Psychopharmacol & Biol Psychiatr* 9:589-592, 1985.

135. Chouinard G, McClure D, Nair NPV, Grof P, Max P, Merskey H, Westin JA: A Canadian multicenter clinical trial of zimelidine and amitriptyline in the treatment of patients with major depressive disorder. Selected papers from the 14th CINP Congress, Florence, Italy, 1984. In: Clinical and Pharmacological Studies in Psychiatric Disorders. Biological Psychiatry - New Prospects, Vol. 5. Burrows GD, Norman TR, Dennerstein L (eds). John Libbey & Company Ltd., London, England, pp. 66-71, 1985.
136. Davidson JRT, Dren AT, Feighner JP, Ban T, Chouinard G: Multicenter study of a non-dopamine receptor blocking agent (BW 234U) in schizophrenia. Selected papers from the 14th CINP Congress, Florence, Italy, 1984. In: Clinical and Pharmacological Studies in Psychiatric Disorders. Biological Psychiatry - New Prospects, Vol. 5. Burrows GD, Norman TR, Dennerstein L (eds). John Libbey & Company Ltd., London, England, pp. 196-201, 1985.
137. Beaudry P, Fontaine R, Chouinard G, Annable L: Clonazepam in the treatment of patients with recurrent panic attacks. *J Clin Psychiatry* 47:83-85, 1986.
138. Chouinard G, Annable L, Steinberg S: A controlled clinical trial of fluspirilene, a long-acting injectable neuroleptic, in schizophrenic patients with acute exacerbation. *J Clin Psychopharmacol* 6:21-26, 1986.
139. Fontaine R, Chouinard G: An open clinical trial of fluoxetine in the treatment of obsessive compulsive disorder. *J Clin Psychopharmacol* 6:98-101, 1986.
140. Steiner W, Chouinard G: A case of mania induced by high-dose fluoxetine treatment. (Letter to editor). *Am J Psychiatry* 143:686, 1986.
141. Chouinard G, Annable L, Mercier P, Ross-Chouinard A: A five-year follow-up study of tardive dyskinesia. *Psychopharmacol Bull* 22:259-263, 1986.
142. Chouinard G: Use of clonazepam in the maintenance treatment of manic depressive illness. In: *Biological Psychiatry 1985*, Shagass C. et al. (eds), Elsevier Science Publishing Co., Inc., pp. 723-725, 1986.
143. Chouinard G, Turnier L: An early Phase II clinical trial of remoxipride in schizophrenia with measurement of plasma neuroleptic activity. *Psychopharmacol Bull* 22:267-271, 1986.
144. Chouinard G: Clonazepam in the treatment of mania and panic disorders. Publication subsequent to a symposium organized by the Royal Australian and New Zealand College of Psychiatrists in March 1986. Published by Excerpta Medica Asia Ltd, Hong Kong, p. 13, 1986.

145. Chouinard G, Steiner W: Remoxipride in the treatment of acute mania. *Biol Psychiatry* 21:1429-1433, 1986.
146. Chouinard G, Annable L, Ross-Chouinard A: Supersensitivity psychosis and tardive dyskinesia: a survey in schizophrenic outpatients. *Psychopharmacol Bull* 22:891-896, 1986.
147. Fontaine R, Mercier P, Beaudry P, Annable L, Chouinard G: Bromazepam and lorazepam in generalized anxiety: a placebo controlled study with measurement of drug plasma concentrations. *Acta Psychiatr Scand* 74:451-458, 1986.
148. Chouinard G: Advances in the management of acute mania and bipolar manic-depressive illness. In: *New Concepts in Mania and Panic Disorder: Focus on Clonazepam*. (MEDICINE Publishing Foundation Symposium Series, 20). Toronto: MES Medical Education Services, pp. 1-14, 1986.
149. Chouinard G: Rebound anxiety: incidence and relationship to subjective cognitive impairment. *J Clin Psychiatry Monograph* 4(1): 12-16, 1986.
150. Chouinard G, Annable L, Mercier P, Turnier L: Long-term effects of L-dopa and procyclidine on neuroleptic-induced extrapyramidal and schizophrenic symptoms. *Psychopharmacology Bull* 23:221-226, 1987.
151. Primeau F, Fontaine R, Chouinard G: Poorly controlled EPS: risk factors for NMS. (Letter to editor). *Can J Psychiatry* 32:328-331, 1987.
152. Chouinard G: An early Phase II clinical trial of remoxipride in the treatment of schizophrenia with measurements of prolactin and neuroleptic activity. *J Clin Psychopharmacol* 7:159-164, 1987.
153. Fontaine R, Beaudry P, Beauclair L, Chouinard G: Comparison of withdrawal of buspirone and diazepam: a placebo controlled study. *Prog Neuro-Psychopharmacol & Biol Psychiatr* 11:189-197, 1987.
154. Cohen BM, Chouinard G, Waternaux C, Schachter H, Jones B, Sommer BR: Plasma concentration of neuroleptic and serum prolactin in patients chronically receiving depot fluphenazine: no evidence of tolerance. *Human Psychopharmacology* 2:171-176, 1987.
155. Chouinard G: Clonazepam in acute and maintenance treatment of bipolar affective disorder. *J Clin Psychiatry* 48(10, Suppl):29-36, 1987.
156. Laporta M, Chouinard G, Goldbloom, D, Beauclair L: Hypomania induced by sertraline, a new serotonin reuptake inhibitor. (Letter to Editor). *Am J Psychiatry* 144:1513-1514, 1987.
157. Steinberg S, Steiner W, Chouinard G: Estrogen-progesterone combination: another mood

- stabilizer? (Letter to Editor). *Am J Psychiatry* 144:826, 1987.
158. Langlois S, Kreeft JH, Chouinard G, Ross-Chouinard A, East S, Ogilvie RI: Midazolam: kinetics and effects on memory, sensorium, and haemodynamics. *Br J Clin Pharmacol* 23:273-278, 1987.
159. Germain L, Chouinard G: Treatment of recurrent unipolar major depression with captopril: 1 case report. *Biol Psychiatry* 23:637-641, 1988.
160. Turnier L, Desrosiers P, Chouinard G: Prescrire un antipsychotique pour un problème gastro-intestinal: un risque pour le patient et pour le médecin. *L'Actualité Médicale* 9(9):26-29, 1988.
161. Chouinard G: Clonazepam in the treatment of psychiatric disorders. In: *Use of Anticonvulsants in Psychiatry: Recent Advances*. Eds. McElroy SL, Pope HG, Oxford Health Care, Inc., Clifton, New Jersey, pp. 43-58, 1988.
162. Beaudry P, Chouinard G: Defining the diagnosis of mania. *Diagnosis* 5:85-97, 1988.
163. Chouinard G: Additional comments on benzodiazepine withdrawal. *CMAJ* 139:119-120, 1988.
164. Chouinard G, Annable L, Ross-Chouinard A, Mercier P: A 5-year prospective longitudinal study of tardive dyskinesia: factors predicting appearance of new cases. *J Clin Psychopharmacol* 8(4):21S-26S, 1988.
165. Beauclair L, Chouinard G: Anxiolytiques et hypnotiques. In: *Manuel de Psychiatrie Clinique: approche bio-psycho-sociale*. Eds. P. Lalonde and F. Grunberg. Gaëtan Morin, Quebec, pp. 984-1007, 1988.
166. Chouinard G, Beauclair L: Antipsychotiques. In: *Manuel de Psychiatrie Clinique: approche bio-psycho-sociale*. Eds. P. Lalonde and F. Grunberg. Gaëtan Morin, Quebec, pp. 1008-1037, 1988.
167. Beauclair L, Chouinard G: Antidépresseurs et électroconvulsivothérapie. In: *Manuel de Psychiatrie Clinique: approche bio-psycho-sociale*. Eds. P. Lalonde and F. Grunberg. Gaëtan Morin, Quebec, pp. 1038-1057, 1988.
168. Chouinard G, Beauclair L: Stabilisateurs de l'humeur et antimaniaques. In: *Manuel de Psychiatrie Clinique: approche bio-psycho-sociale*. Eds. P. Lalonde and F. Grunberg. Gaëtan Morin, Quebec, pp. 1058-1077, 1988.
169. Chouinard G: The use of benzodiazepines in the treatment of manic depressive illness. *J Clin Psychiatry* 49(Suppl):15-19, 1988.
170. Bélanger-Annable M-C, Chouinard G: Depression: A treatable illness? Eli Lilly Canada

- Inc., 1988.
171. Germain L, Chouinard G: Captopril treatment of major depression with serial measurements of blood cortisol concentrations. *Biol Psychiatry* 25:489-493, 1989.
172. Fontaine R, Chouinard G: Fluoxetine in the long-term treatment of obsessive compulsive disorder. *Psychiatric Annals* 19:88-91, 1989.
173. Turnier L, Desrosiers P, Chouinard G: Dyskinésie respiratoire induite par le retrait d'un antidopaminergique prescrit pour un problème digestif fonctionnel. *Le clinicien* 4:55-68, 1989.
174. Chouinard G: La psychose de supersensibilité induite par les neuroleptiques. In: *Dictionnaire des neuroleptiques*. Colonna L, Petit M, Lépine JP (eds.), Éditions J.B. Baillière, Paris, pp. 295-298, 1989.
175. Chouinard G, Annable L, Campbell W: A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia. *J Clin Psychopharm* 9:247-253, 1989.
176. Chouinard G: Clonazepam in treatment of bipolar psychotic patients after discontinuation of neuroleptics. *Am J Psychiatry (Ltr to ed)* 146:1642, 1989.
177. Chouinard G: Recent advances in the treatment of depression. Report of a Symposia Series - Vancouver, Montreal, Toronto - May 1990, The Medicine Group, 1990.
- 178*. Chouinard G, Beauclair L, Geiser R, Etienne P: A pilot study of magnesium aspartate hydrochloride (Magnesiocard) as a mood stabilizer for rapid cycling bipolar affective disorder patients. *Prog Neuro-Psychopharmacol & Biol Psychiatry* 14:171-180, 1990.
*Winner of 3rd Prize, Wyeth-Ayerst Award for New Research, North America, VIII World Congress of Psychiatry, Athens, Greece, October 12-19, 1989.
179. Turnier L, Chouinard G, Desrosiers P: La dépression masquée. *Le Médecin du Québec*, pp. 93-96, mars 1990.
180. Turnier L, Chouinard G: Effet anti-koro d'un antidépresseur tricyclique. *Revue canadienne de psychiatrie* 35:331-333, 1990.
181. Desrosiers P, Turnier J, Hillel J, Chouinard G: Le diagnostic de la maladie bipolaire. *Le Médecin du Québec*, pp. 69-79, August 1990.
182. Steiner W, Laporta M, Chouinard G: Neuroleptic-induced supersensitivity psychosis in patients with bipolar affective disorder. *Acta Psychiatrica Scand* 81(5):437-440, 1990.
183. Sultan S, Chouinard G, Beaudry P: Antiepileptic drugs in the treatment of neuroleptic-induced supersensitivity psychosis. *Prog Neuro-Psychopharmacol & Biol Psychiatry* 14:431-438, 1990.

184. Laporta M, Archambault D, Ross-Chouinard A, Chouinard G: Articulatory impairment associated with tardive dyskinesia. *J Nerv and Men Disease* 178:660-662, 1990.
185. Chouinard G, Landry P: New drugs for the treatment of generalized anxiety, panic and obsessive-compulsive disorders. In: *Handbook of Anxiety, Vol. 4: The Treatment of Anxiety*. Edited by Noyes R. Jr., M. Roth and G.D. Burrows. Elsevier Science Publishers, B.V., pp. 271-289, 1990.
186. Chouinard G, Beauclair L, Geiser R, Etienne P: Magnesium aspartate hydrochloride (Magnesiocard) as a mood stabilizer for rapid cycling bipolar affective disorder patients. In: *Psychiatry: A world perspective*. C.N. Stefanis et al., (eds), Elsevier Science Publishers B.V., Vol. 3, pp.368-376, 1990.
187. Landry P, Chouinard G: Obsessive-compulsive disorder: Pathogenesis and fluoxetine treatment. *Reviews in Contemporary Pharmacotherapy* 1:61-74, 1990.
188. Chouinard G, Sultan S: Treatment of supersensitivity psychosis with antiepileptic drugs: Report of a series of 43 cases. *Psychopharmacology Bulletin* 26:337-341, 1990.
189. Chouinard G, A placebo-controlled clinical trial of remoxipride and chlorpromazine in newly admitted schizophrenic patients with acute exacerbation. *Acta Psychiatr Scand* 82(Suppl.358):111-119, 1990.
190. Teboul E, Chouinard G: A guide to benzodiazepine selection: Part I: Pharmacological aspects. *Can J Psychiatry* 35:700-710, 1990.
191. Chouinard G, Goodman W, Greist J, Jenike M, Rasmussen S, White K, Hackett E, Gaffney M, Bick PA: Results of a double-blind placebo controlled trial of a new serotonin uptake inhibitor, sertraline, in the treatment of obsessive-compulsive disorder. *Psychopharmacology Bulletin* 26:279-284, 1990.
192. Fontaine R, Beaudry P, Le Morvan P, Beauclair L, Chouinard G: Zopiclone and triazolam in insomnia associated with generalized anxiety disorder: a placebo-controlled evaluation of efficacy and daytime anxiety. *Int Clin Psychopharmacol* 5: 173-183, 1990.
193. Reimherr FW, Chouinard G, Cohn CK, et al: Antidepressant efficacy of sertraline: A double-blind, placebo- and amitriptyline-controlled multicenter comparison study in outpatients with major depression. *J Clin Psychiatry* 51(Suppl B):18-27, 1990.
194. Chouinard G: Severe cases of neuroleptic-induced supersensitivity psychosis: Diagnostic criteria for the disorder and its treatment. *Schizophrenia Research* 5:21-33, 1990.
195. Teboul E, Chouinard G: A guide to benzodiazepine selection. Part II: Clinical aspects. *Can J Psychiatry* 36:62-73, 1991.
196. Landry P, Chouinard G, Primeau F: Lithium-tryptophan combination in the maintenance

- treatment of bipolar affective illness. *Lithium* 2:135-140, 1991.
197. Chouinard G: Tryptophan and its role in the step-care approach to the treatment of affective disorders. *The Canadian Review of Affective Disorders* 1(2):1, 1991.
198. Murphy BEP, Dhar V, Ghadirian AM, Chouinard G, Keller R: Response to steroid suppression in major depression resistant to antidepressant therapy. *J Clin Psychopharmacol* 11:121-126, 1991.
199. Chouinard G: Fluoxetine and preoccupation with suicide (Ltr to ed). *Am J Psychiatry* 148:1258-1259, 1991.
200. Chouinard G, Safadi G, Beauclair L: Zuclopenthixol acetate and liquid oral haloperidol in the treatment of schizophrenic patients with acute exacerbation. In: *Biological Psychiatry Vol. 1, Proceedings of the 5th World Congress of Biological Psychiatry*, Racagni G, Brunello N, Fukuda T (eds), Excerpta Medica, Amsterdam, pp. 560-562, 1991.
201. Chouinard G: A double-blind, multicenter, placebo-controlled study of sertraline in obsessive-compulsive disorder. In: *Biological Psychiatry Vol. 2, Proceedings of the 5th World Congress of Biological Psychiatry*, Racagni G, Brunello N, Fukuda T (eds), Excerpta Medica, Amsterdam, p. 871, 1991.
202. Bischoff S, Baumann P, Krauss J, Maitre L, Vassout A, Stroni A, Chouinard G: CGP 25454A, a novel and selective presynaptic dopamine autoreceptor antagonist. *Naunyn Schmiedebergs Arch Pharmacol* 350 (3) 230-8, 1994.
203. Chouinard G, Sultan S: A case of Parkinson's disease exacerbated by fluoxetine. *Human Psychopharmacology* 7:63-66, 1992.
204. Murphy BEP, Dhar V, Ghadirian AM, Chouinard G, Keller R: Theoretical basis for response to steroid suppression in major depression - Reply. (Ltr to ed.) *J Clin Psychopharmacol* 12:143-144, 1992.
205. Chouinard G: The emerging role of valproic acid in the therapy of bipolar disorder. Summary Proceedings of Satellite Symposium of the 41st Annual Canadian Psychiatric Association Meeting 1991, pp. 2-4, 1992.
206. Chouinard G, Annable L: Risk factors in tardive dyskinesia and supersensitivity psychosis. In: *Movement Disorders in Neurology and Neuropsychiatry*. Edited by Joseph AB, Young RR, Boston, Blackwell Scientific Publications, Boston, pp. 51-59, 1992.
207. Chouinard G: Sertraline in the treatment of obsessive compulsive disorder: Two double-blind, placebo-controlled studies. *International Clinical Psychopharmacology* 7(Suppl 2):37-41, 1992.
208. Chouinard G, Saxena BM, Nair NP, Kutcher SP, Bakish D, Bradwejn J, Sharma V,

- Remick RA, Kukha-Mohamad SA: Efficacy of safety of brofaromine in depression: A Canadian multicentre placebo-controlled trial and a review of comparative controlled studies. *Clinical Neuropharmacology* 15 [Suppl] Pt A:426A-427A, 1992.
209. Chouinard G, Jones BD, Remington G, Bloom D, Addington D, MacEwan GW, Labelle A, Beauclair L, Arnott W: A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. *J Clin Psychopharmacol* 13:25-40, 1993.
210. Chouinard G, Saxena BM, Nair NPV, Kutcher SP, Bakish D, Bradwejn J, Kennedy SH, Sharma V, Remick RA, Kukha-Mohamad SA, Beauclair L, Snaith J, D'Souza J: Brofaromine in depression: A Canadian multicenter placebo trial and a review of standard drug comparative studies. *Clinical Neuropharmacology* 16:S51-S54, 1993.
211. Chouinard G, Annable L, Turnier L, Holobow N, Szkrumelak N: A double-blind randomized clinical trial of rapid tranquilization with I.M. clonazepam and I.M. haloperidol in agitated psychotic patients with manic symptoms. *Can J Psychiatry* 38:(suppl. 4):S114-S121, 1993.
212. Addington DE, Jones B, Bloom D, Chouinard G, Remington G, Albright P: Reduction of hospital days in chronic schizophrenic patients treated with risperidone. A retrospective study. *Clin Ther* 15(5):917-926, 1993.
213. Chouinard G, Arnott W: Clinical Review of Risperidone. *Can J Psychiatry* 28:(suppl. 3):S89-S95, 1993.
214. Miller R, Chouinard G: Loss of striatal cholinergic neurons as a basis of tardive and L-dopa-induced dyskinesias, and neuroleptic-induced supersensitivity psychosis. *Biol Psychiatry* 34:713-738, 1993.
215. Chouinard G, Vainer JL, Bélanger M-C, Turnier L, Beaudry P, Roy J-Y, Miller R: Risperidone and clozapine in the treatment of drug-resistant schizophrenia or neuroleptic-induced supersensitivity psychosis. *Prog Neuro-Psychopharmacology & Biol Psychiatry* 18:1129-1141, 1994.
216. Beauclair L, Fontaine R, Annable L, Holobow N, Chouinard G: Clonazepam in the treatment of panic disorder: A double-blind, placebo-controlled trial investigating the correlation between clonazepam concentrations in plasma and clinical response. *J Clin Psychopharmacol* 14:111-118, 1994.
217. Chouinard G, Safadi G, Beauclair L: A double-blind controlled study of intramuscular zuclopenthixol acetate and liquid oral haloperidol in the treatment of schizophrenic patients with acute exacerbation. *J Clin Psychopharmacol* 14:377-384, 1994.

218. Chouinard G, Saxena BM, Nair NPV, Kutcher SP, Bakish D, Bradwejn J, Kennedy SH, Sharma V, Remick RA, Kukha-Mohamad SA, Bélanger M-C, Snaith J, Beauclair L, Pohlmann H, D'Souza J: A Canadian multicentre placebo-controlled study comparing a fixed dose of brofaromine, a reversible selective MAO-A inhibitor, in the treatment of major depression. *J Affective Disord* 32:105-114, 1994.
219. Vainer J, Chouinard G: Interaction between caffeine and clozapine. (Ltr to ed). *J Clin Psychopharmacol* 14:284-285, 1994.
220. Brouillette M-J, Chouinard G, Lalonde R: Didanosine-induced mania in HIV infection. (Let to Ed.). *Am J Psychiatry* 151:1839-1840, 1994.
221. Seeman P, Ulpian C, Chouinard G, Van Tol Hubert HM, Hy D, Lieberman JA, Sminovitch K, Liu ISC, Waye J, Voruganti P, Hudson C, Serjeant GR, Masibay AS, Seeman MV: Dopamine D4 Receptor Variant, D4GLYCINE194, in Africans but not in Caucasians: No association with schizophrenia. *Am J Med G (Neuropsychiatric Genetics)* 54:384-390, 1994.
222. Reith J, Benkelfat C, Sherwin A, Yasuhara Y, Kuwabara H, Andermann F, Bachneff S, Cumming P, Diksic M, Dyve SE, Etienne P, Evans AC, Lal S, Shevell M, Savard G, Wong DF, Chouinard G, Gjedde A: Elevated dopa decarboxylase activity in living brain of patients with psychosis. *Proc Natl Acad Sci* 91:11651-11654, 1994.
223. Cunningham LA, Borison RL, Carman JS, Chouinard G, Crowder JE, Diamon BI, Fischer DE, Hearst E: A comparison of venlafaxine, trazodone, and placebo in major depression. *J Clin Psychopharmacol* 14:99-106, 1994.
224. Chouinard G: Neuroleptiques: Spécificité d'action et association? Dans: Stratégies thérapeutiques à long terme dans les psychoses schizophréniques. Conférence de consensus. Textes des experts (chapitre de livre). Paris (France): Editions Frison-Roche, pp. 135-148, 1994.
225. Mollér H-J, Müller H, Borison RL, Schooler NR, Chouinard G: A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re-evaluation of the North American risperidone study. *Eur Arch Psychiatry Clin Neurosci* 245:45-49, 1995.
226. Ghadirian AM, Engelsmann F, Dhar V, Filipini D, Keller R, Chouinard G, Pearson Murphy BE: The Psychotropic Effects of Inhibitors of Steroid Biosynthesis in Depressed Patients Refractory to Treatment. *Biol Psychiatry* 37:369-375, 1995.
227. Greist JH, Chouinard G, DuBoff E, Halaris A, Kim SW, Koran L, Liebowitz M, Lydiard RB, Rasmussen S, White K, Sikes C: Double-blind parallel comparison of three dosages of

- sertraline and placebo in outpatients with obsessive compulsive disorder. *Arch Gen Psychiatry* 52:289-295, 1995.
228. Nelson J, Chouinard G: Le trouble obsessionnel-compulsif n'est pas un trouble anxieux. *Confrontations psychiatriques*, 36:139-173, 1995.
229. Chouinard G: Effects of risperidone in tardive dyskinesia: An analysis of the Canadian Multicenter Risperidone Study. *J Clin Psychopharmacol* 15:36S-44S, 1995.
230. Chouinard G: Critique of the Canadian multicenter, placebo-controlled study of risperidone and haloperidol. Reply to DP^{rsP} Musser and Kirisci. *J Clin Psychopharmacol* 15:226-230, 1995.
231. Greist JH, Jefferson JW, Kobak KA, Chouinard G, Duboff E, Halaris A, Kim SW, Koran L, Liebowitz M, Lydiard B, Mcelroy S, Mendels J, Rasmussen S, White K, Flicker C: A one-year double-blind placebo-controlled fixed dose study of sertraline in the treatment of obsessive-compulsive disorder. *Int Clin Psychopharmacol* 10:57-65, 1995.
232. Ghadirian AM, Annable L, Bélanger M-C, Chouinard G: A cross-sectional study of parkinsonism and tardive dyskinesia in lithium-treated affective disordered patients. *J Clin Psychiatry* 57:22-28, 1996.
233. Nelson J, Chouinard G: Benzodiazepines: Mechanisms of Action and Clinical Indications. In: *Brain Mechanisms and Psychotropic drugs*. Eds. A Baskys and GJ Remington, CRC Press, Boca Raton, Florida, pp. 213-238, 1996.
234. Chouinard G: Concomitant use of antipsychotics with risperidone. (Ltr to ed). *Am J Health-Syst Pharm* 53:(4)443, 1996.
235. Nelson J, Chouinard G. Benzodiazepines: An update on their mechanisms of action. *Can J Clin Pharmacol* 3:(2)75-82, 1996.
236. Chouinard G, Bélanger M-C, Beauclair L, Sultan S, Pearson-Murphy BE: Potentiation of fluoxetine by aminoglutethimide, a steroid suppressant, in obsessive-compulsive disorder resistant to SSRIs: A case report. *Prog Neuro-Psychopharmacol and Biol Psychiat* 20:(6)1067-1079, 1996.
237. Lapierre YD, Joffe R, McKenna K, Bland R, Kennedy S, Ingram P, Reesal R, Rickhi BG, Beauclair L, Chouinard G, Annable L: Moclobemide versus Fluoxetine in the Treatment of Major Depressive Disorder in Adults. *J Psychiatry Neurosci* 22:118-126, 1997.
238. Chouinard G, Albright PS: Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol. *J Clin Psychopharmacol* 18:298-307, 1997.
239. Fournier JP, Lane RM, Chouinard G, Watson DB, Amin M, Remick RA, Thorpe LU: A

- double-blind comparison of sertraline and imipramine in outpatients with major depression: acute (8 weeks) and continuation (16 weeks) treatment. *Human Psychopharmacology - Clinical and Experimental* 12:203-215, 1997.
240. Marder S, Davis JM, Chouinard G: The Effects of Risperidone on the Five Dimensions of Schizophrenia Derived by Factor Analysis: Combined Results of the North American Trial. *Journal of Clinical Psychiatry* 58:538-546, 1997.
241. Chouinard G, Beauclair L, Bélanger M-C: Gabapentin: Long-term antianxiety and hypnotic effects in psychiatric patients with comorbid anxiety-related disorders. Letter to Editor. *Canadian Journal of Psychiatry* 43:305, 1998.
242. Dallal A, Chouinard G: Withdrawal or rebound symptoms associated with abrupt discontinuation of venlafaxine. Letter to Editor. *J Clin Psychopharmacol* 18:343-344, 1998.
243. Looper KJ, Chouinard G: Beneficial effects of combined L-dopa and central anticholinergic in a patient with severe drug-induced parkinsonism and tardive dystonia. Letter to Editor. *Canadian Journal of Psychiatry* 43:646-647, 1998.
244. Chouinard G, Kopala L, Labelle A, Beauclair L, Johnson SV, Singh KI, Ris-Can-3 Study Group: Phase IV multicentre clinical study of risperidone in the treatment of outpatients with schizophrenia. *Canadian Journal of Psychiatry* 43:1018-1025, 1998.
245. Chouinard G, Annable L: Risk factors in tardive dyskinesia and supersensitivity psychosis. In: Drs. A.B. Joseph and R.R. Young (eds). *Movement Disorders in Neurology and Neuropsychiatry*. 2nd ed. Blackwell Scientific Publications, Boston, Chapter 6, p. 45, 1999.
246. Margolese H, Chouinard G: Olanzapine-Induced Neuroleptic Malignant Syndrome in a patient with Mental Retardation. Letter to the Editor. *American Journal of Psychiatry* 156:1115-1116, 1999.
247. Nelson J, Chouinard G: Guidelines for Clinical Use of Benzodiazepines: Pharmacokinetics, Dependency, Rebound, and Withdrawal. *Canadian Journal of Clinical Pharmacology* 6:69-83, 1999.
248. Chouinard G, Saxena B, Bélanger M-C, Ravindran A, Bakish D, Beauclair L, Morris P, Nair NPV, Manchanda R, Reesal R, Remick R, O'Neill MC: A Canadian multicentre, double-blind study of paroxetine and fluoxetine in major depressive disorder. *Journal of Affective Disorders* 54:39-48, 1999.
249. Chouinard G, Lefko-Singh K, Teboul E: Metabolism of anxiolytics and hypnotics: benzodiazepines, buspirone, zopiclone and zolpidem. Review. (Chapter) In: G.B. Baker

- (Guest Editor). *Drug Metabolism and Psychiatry. Cellular and Molecular Neurobiology*. Aug;19(4):533-552, 1999.
250. Chouinard G, Miller R: A new Rating Scale for Psychotic Symptoms (RSPS). Part I. Theoretical Principles and Subscale 1: Perception Symptoms (Hallucinations and Illusions). *Schizophrenia Research* 38:101-122, 1999.
251. Chouinard G, Miller R: A new Rating Scale for Psychotic Symptoms (RSPS). Part II. Subscale 2: Distraction Symptoms (Catatonia and Passivity Experiences). Subscale 3: Delusions and Semi-Structured Interview (SCI-RSPS). *Schizophrenia Research* 38:123-150, 1999.
252. Ricard N, Sauriol L, Bélanger M-C, Chouinard G: Direct cost of psychiatric care in schizophrenic patients presenting in Emergency Unit: Retrospective Cohort Study. *Psychiatric Services* 50:(10):1287-1288, 1999.
253. Beauclair L, Radoi-Andraous D, Chouinard G: Selective Serotonin/Noradrenaline Reuptake Inhibitors (SNRIs). (Chapter). In: Benjamin J. Sadock, Virginia A. Sadock (eds). *Kaplan & Sadock's Comprehensive Textbook of Psychiatry, Seventh Edition*, Lippincott Williams & Wilkins, Philadelphia, PA, 2000, Vol. 2, no. 31.24, p. 2427-2432.
254. Versiani M, Amin M, Chouinard G: A double-blind, placebo-controlled study with reboxetine in inpatients with severe major depressive disorder. *Journal of Clinical Psychopharmacology* 20:28-34, 2000.
255. Margolese HC, Chouinard G: Serotonin Syndrome From Addition of Low-Dose Trazodone to Nefazodone (letter). *American Journal of Psychiatry*, 157:1022, 2000.
256. Barsoum A, Kolivakis TT, Margolese HC, Chouinard G: Diphenhydramine (Unisom®, Benadryl®), a Central Anticholinergic and Antihistaminic, Abuse with Massive Ingestion in a Patient with Schizophrenia. Letter to Editor. *Canadian Journal of Psychiatry* 45:846-847, 2000.
257. Pande AC, Pollack MH, Crockatt J, Greiner M, Chouinard G, Lydiard RB, Barr Taylor C, Dager SR, Shiovitz T: Placebo-Controlled Study of Gabapentin Treatment of Panic Disorder. *Journal of Clinical Psychopharmacology* 20:467-471, 2000.
258. Margolese HC, Chouinard G, Beauclair L, Rubino M: Cutaneous vasculitis induced by the selective serotonin reuptake inhibitor paroxetine in a patient with obsessive-compulsive disorder. Letter to Editor. *American Journal of Psychiatry* 158:497, 2001.
259. Beauclair L, Chouinard G: Stabilisateurs de l'humeur. (Chapter) In: P. Lalonde, J. Aubut, F. Grunberg, and coll. (eds). *Psychiatrie Clinique. Une approche bio-psycho-*

- sociale. Tome II: Spécialités, traitements, sciences fondamentales et sujets d'intérêt. Gaëtan Morin, Boucherville, Quebec, Canada, 2001, Chapter 45, p. 1205-1225.
260. Margolese HC, Chouinard G, Walters Larach V, Beauclair L: Relationship between antipsychotic-induced akathisia and tardive dyskinesia and suicidality in schizophrenia: impact of clozapine and olanzapine. *Acta Psychiatrica Belgica* 101:128-144, 2001.
261. Kolivakis TT, Margolese HC, Beauclair L, Chouinard G: Olanzapine-Induced Somnambulism In Patients with Schizophrenia. Letter to Editor. *American Journal of Psychiatry* 158:1158, 2001.
262. Miller R, Chouinard G: Les médicaments antipsychotiques: Évolution ou Révolution?, In: Jean-Pierre Olié, Jean Daléry, Jean-Michel Azorin (ed.). III. Médicaments antipsychotiques et situations pathologiques. «Les troubles schizoaffectifs. Typologie unidimensionnelle et principes thérapeutiques», (Chapter). ETICOM-Acanthe, Paris, France, 2001 pp. 397-412.
263. Kolivakis TT, Margolese HC, Beauclair L, Chouinard G: Clozapine for First-Episode Schizophrenia. Letter to Editor. *American Journal of Psychiatry* 159:317, 2002.
264. Dion Y, Annable L, Sandor P, Chouinard G: Risperidone in the treatment of Tourette Syndrome: A double-blind, placebo-controlled trial. *Journal of Clinical Psychopharmacology* 22:31-39, 2002.
265. Margolese HC, Chouinard G, Beauclair L, Bélanger M-C: Therapeutic Tolerance and Rebound Psychosis during Quetiapine Maintenance Monotherapy in Patients with Schizophrenia and Schizoaffective Disorder. *Journal of Clinical Psychopharmacology* 22:347-352, 2002.
266. Margolese HC, Chouinard G, Beauclair L, Miller R: Using the Rating Scale for Psychotic Symptoms to Characterize Delusions Expressed in a Schizophrenia Patient With "Internet Psychosis". Letter to Editor. *Canadian Journal of Psychiatry* 47:485, 2002.
267. Levy E, Margolese HC, Chouinard G: Topiramate produced weight loss following olanzapine induced weight gain in schizophrenia. Letter to Editor. *Journal of Clinical Psychiatry* 63:1045, 2002.
268. Jablonowski K, Margolese HC, Chouinard G: Gabapentin-induced paradoxical exacerbation of psychosis in a patient with schizophrenia. Letter to Editor. *Canadian Journal of Psychiatry* 47:975-976, 2002.
269. Bhanji N, Margolese HC, St-Laurent M, Chouinard G: Dysphoric mania induced by high-dose mirtazapine: a case for "norepinephrine syndrome"? *International Clinical Psychopharmacology* 17:319-322, 2002.

270. Meltzer HY, Alphas L, Green AI, Altamura AC, Anand R, Bertoldi A; Bourgeois M; Chouinard G, Islam MZ, Kane J, Krishnan R; Lindenmayer JP; Potkin S: Clozapine Treatment for Suicidality in Schizophrenia International Suicide Prevention Trial (InterSePT). *Arch Gen Psychiatry* 60:82-91, 2003.
271. Margolese HC, Beauclair L, Szkrumelak N, Chouinard G: Hypomania Induced by Adjunctive Lamotrigine. Letter to Editor. *American Journal of Psychiatry* 160:1, 2003.
272. Bhanji N, Margolese HC, Chouinard G, Turnier L: Late-Onset Agranulocytosis in a Patient With Schizophrenia After 17 Months of Clozapine Treatment. Letter to Editor. *Journal of Clinical Psychopharmacology* 23:522-523, 2003.
273. Chouinard G: Issues in the Clinical Use of Benzodiazepines. *Journal of Clinical Psychiatry, Supplement Preview* 64:5-7, 2003.
274. Wright P, Lindborg SR, Birkett M, Meehan K, Jones B, Alaka K, Ferchland-Howe I, Pickard A, Taylor CC, Roth J, Battaglia J, Bitter I, Chouinard G, Morris P, Breier A: Intramuscular Olanzapine and Intramuscular Haloperidol in Acute Schizophrenia: Antipsychotic Efficacy and Extrapyramidal Safety During the First 24 Hours of Treatment. *Can J Psychiatry* 48:716-721, 2003.
275. Levy E, Margolese H, Sultan S, Chouinard G: Obsessive-Compulsive Symptoms in Schizophrenia Induced by Risperidone and Responding to Fluoxetine. (Letter to editor). *Can J Psychiatry* 48:709-710, 2003.
276. Margolese HC, Chouinard G, Beauclair L, Bélanger M-C: Therapeutic Tolerance to Quetiapine: Response to Drs. Goldstein and Macfadden. Letter to the Editors. *Journal of Clinical Psychopharmacology* 24:103-104, 2004.
277. Bhanji N, Chouinard G, Margolese HC: A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia. *European Neuropsychopharmacology* 14:87-92, 2004.
278. Kolivakis TT, Beauclair L, Margolese HC, Chouinard G: Long-term adjunctive lamotrigine to antipsychotic monotherapy in schizophrenia, further evidence. Letter to the Editor. *Can J Psychiatry* 49:280, 2004.
279. Chouinard G: Considerations in Developing Criteria for Drug Induced Movement Posture Disorder: Tardive Dyskinesia. *Journal of Clinical Psychiatry, Visuals*:2-4, March 2004.
280. Chouinard G: Issues in the Clinical Use of Benzodiazepines: Potency, Withdrawal, and Rebound. *Journal of Clinical Psychiatry*: 65 (Suppl 5) 7-12, 2004.
281. Chouinard G: Le traitement pharmacologique du patient difficile et de la dangerosité. Les dangers de la criminologie à la psychopathologie, entre justice et psychiatrie.

- Éditions John Libbey Eurotext, sous la direction de Christiane de Beaurepaire, Michel Bénézech, Christian Kottler, Paris, France, 2004, Traitement de la dangerosité, p. 325-334.
282. Chouinard G: New Nomenclature for Drug-Induced Movement Disorders Including Tardive Dyskinesia. *Journal of Clinical Psychiatry*: 65 (Suppl 9) 9-15, 2004.
283. Corruble E, Awad H, Chouinard G, Hardy P: ECT in Delusional Depression Associated with Multiple Sclerosis. *Am J Psychiatry* 161: 1715, 2004.
284. Levy E, Margolese HC, Annable L, Chouinard G: Diabetes and Tardive Dyskinesia, Parkinsonism, Akathisia in Schizophrenia: A Retrospective Study Applying 1998 Diabetes Health Care Guidelines to Antipsychotic Use. *Can J Psychiatry* 49:215-219, 2004.
285. Alphas L, Anand R., Islam MZ, Meltzer HY, Kane J, Krishnan R, Green AI, Potkin S, Chouinard G, Lindenmayer JP, Kerwin R: The International Suicide Prevention Trial (InterSePT): Rationale and Design of a Trial Comparing the Relative Ability of Clozapine and Olanzapine to Reduce Suicidal Behavior in Schizophrenic and Schizoaffective Patients. *Schizophrenia Bulletin* 2004; 30(3):577-86.
286. Esposito D, Corruble E, Hardy P, Chouinard G: Risperidone-Induced Morning Pseudoneutropenia. *Let to Ed. Am J Psychiatry* 162:397, 2005.
287. Bhanji N, Chouinard G, Hoffman L, Margolese HC. Seizures, Coma, and Coagulopathy following Olanzapine Overdose. *Can J Psychiatry*, 50:126-127, 2005.
288. Margolese H, Chouinard G, Kolivakis T, Beauclair L, Miller R: Tardive Dyskinesia in the Era of Typical and Atypical Antipsychotics (Part 1): Pathophysiology and Mechanisms of Induction. *Can J Psychiatry* 50:541-547, 2005.
289. Chouinard G, Margolese HC: Manual for the Extrapiramidal Symptom Rating Scale (ESRS). *Schizophrenia Research* 76:247-265, 2005.
290. Pfeffer G, Chouinard G, Margolese HC: Gabapentin in the Treatment of Antipsychotic-Induced Akathisia in Schizophrenia. *International Clinical Psychopharmacology* 20(3):179-181, 2005.
291. Gharabawi GM, Bossie CA, Lasser RA, Turkoz I, Rodriguez S, Chouinard G: Abnormal Involuntary Movement Scale (AIMS) and Extrapiramidal Symptom Rating Scale (ESRS): Cross-Scale Comparison in Assessing Tardive Dyskinesia. *Schizophrenia Research* 77:119-128, 2005.
292. Corruble E, Chouinard G: Differences between second-generation antidepressants? Rapid response. *Ann Inter Med*, 2005
293. Margolese H, Chouinard G, Kolivakis T, Beauclair L, Miller R, Annable L: Tardive Dyskinesia in the Era of Typical and Atypical Antipsychotics (Part 2): Incidence and

- Management Strategies in Patients with Schizophrenia. *Can J Psychiatry* 50:541-547, 2005.
294. Esposito D, Brocvielle H, Becquemont L, Chouinard G, Hardy P, Corruble E: Risperidone-Induced Immunoallergic Hepatitis. *Let to Ed. Am J Psychiatry* 162(10):1984, 2005.
295. Esposito D, Chouinard G, Hardy P, Corruble E: Successful initiation of clozapine treatment despite morning pseudoneutropenia. *Int J Neuropsychopharmacol*: Aug; 9(4):489-91.[Epub2005 Sep28, 1-3, 2005] 2006.
296. Corruble E, Buhl C, Esposito D, Schuster JP, Chouinard VA, Hardy P, Chouinard G: Psychosis Associated with Elevated Trough Tacrolimus Blood Concentrations after joint combined kidney and pancreas transplantation, treated with olanzapine. *Let to Ed. Int J Neuropsychopharmacol* Aug;9(4) :493-4 [2005 Nov 29;:1-2 Epub], 2006.
297. Bhanji N, Chouinard G, Kolivakis T, Margolese HC: Persistent Tardive Rebound Panic Disorder, Rebound Anxiety and Insomnia following Paroxetine Withdrawal: A review of rebound-withdrawal phenomena. *Can J Clin Pharmacol* 13 (1): e69-e74, 2006.
298. Chouinard G: The Search for New Off Label Indications for Antidepressant, Antianxiety, Antipsychotic and Anticonvulsant Drugs: Part 1: Heinz Lehmann Award 2004. *J Psychiatry Neurosci* 31(3) :168-176, 2006.
299. Chouinard G: Inter-relationships Between Psychiatric Symptoms and Drug-Induced Movement Disorder (DIMD): Part 2: Heinz Lehmann Award 2004. *J Psychiatry Neurosci* 31(3) :177-180, 2006.
300. Schuster JP, Buhl C, Archambaud F, Hardy P, Chouinard G, Prigent A, Corruble E. Using striatal dopamine transporter single photon emission computed tomography imaging to rule out Dementia with Lewy Bodies in elderly patients with antipsychotic-induced parkinsonism. *Psychiatry Clin Neurosci* 61(2):206, 2007
301. Buhl C, Riaux A, Andraud F, Chouinard G, Hardy P, Corruble E. Nine-year prophylactic maintenance electroconvulsive therapy in an 89-year-old woman with recurrent psychotic major depressive disorder. *Am J Geriatr Psychiatry* 15(4):357, 2007.
302. Lévy E, Agbokou C, Ferreri F, Chouinard G, Margolese HC. Topiramate-induced weight loss in schizophrenia: a retrospective case series study. *Can J Clin Pharmacol* 14(2):234-9, 2007
303. Chouinard G, Chouinard VA. Atypical antipsychotics: CATIE study, drug-induced movement disorder and resulting iatrogenic psychiatric-like symptoms, supersensitivity rebound psychosis and withdrawal discontinuation syndromes. *Psychother Psychosom*

- 77(2): 69-77, 2008.
304. Peretti CS, Ferreri F, Blanchard F, Bakchine S, Peretti CR, Dobrescu A, Chouinard VA, Chouinard G. Normal and pathological aging of attention in presymptomatic Huntington's, Huntington's and Alzheimer's Disease, and nondemented elderly subjects. *Psychother Psychosom* 77(3): 139-46, 2008.
305. Breil F, Verstuyft C, Orostegui L, Buhl C, Alvarez JC, Chouinard G, Becquemont L, Corruble E. Non-response to consecutive antidepressant therapy caused by CYP2D6 ultrarapid metabolizer phenotype. *Int J Neuropsychopharmacol* 11(5): 727-8, 2008.
306. Corruble E, Chouinard VA, Letierce A, Gorwood P, Chouinard G: DSM Bereavement Exclusion for Major Depression is not Relevant to Severity and Pattern of Symptoms. *J Clin Psychiatry* (E-pub 2009 Jun30). Aug; 70 (8): 1091-7, 2009.
307. Bandelow B, Chouinard G, Bobes J, Ahokas A, Eggens I, Liu S, Eriksson H: Extended release quetiapine fumarate (quetiapine XR) :a once a day monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study. *Int J Neuropsychopharmacol* (Epub 2009 Aug 20) 13(3): 305-320, 2010.
308. Corruble E, Gorwood PA, Chouinard G: V Code for Bereavement Paula Clayton Reply. *J Clin Psychiatry* 71(3): 360, Mar 2010.
309. Demily C, Chouinard VA, Chouinard G: Reconnaître les symptômes psychiatriques iatrogènes liés aux antipsychotiques. *L'Encéphale* 36 :417-424, 2010.
310. Chouinard G, Chouinard VA, Corruble E: Beyond DSM-IV Bereavement Exclusion Criterion E for Major Depressive Disorder. *Psychother Psychosom* (Epub Oct 23; 80(1) 4-9 2010) 80: 804-9, 2011.
311. JM Cloos, R Stein, P Rauchs, P Koch, G Chouinard: Addictions aux benzodiazépines: prévalence, diagnostic et traitement. *Encyclopédie Médico Chirurgicale*. EMC (Elsevier Masson SAS, Paris) Psychiatrie, 37-396-A-17, 2011.
312. Peretti CS, Peretti CR, Kozora E, Papathanassiou D, Chouinard VA, Chouinard G: Cognitive Impairment in Systemic Lupus Erythematosus Women with Elevated Autoantibodies and Normal Single Photon Emission Computerized Tomography. *Psychother Psychosom*, Jul 20; 81(5):276-285. [Epub ahead of print] 2012.
313. Belaise C, Gatti A, Chouinard VA, Chouinard G: Patient Online Report of Selective Serotonin Reuptake Inhibitor (SSRI) Induced Persistent Postwithdrawal Anxiety and Mood Disorders. *Psychother Psychosom* 2012; 81: 386-388.
314. Fava GA, Tossani E, Bech P, Berrocal C, Chouinard G, Csillag C, Wittchen HU, Rief W: Emerging Clinical Trends and Perspectives on Comorbid Patterns of Mental Disorders

- in Research. *Int J Methods Psychiatr Res* 23(suppl 1) : 92-101, Jan 2014.
315. Wittchen HU, Knappe S, Andersson G, Araya R, Banos Rivera RM, Barkham M, Bech P, Beckers T, Berger T, Berking M, Berrocal C, Botella C, Carlbring P, Chouinard G, Colom F, Csillag C, Cujipers P, David D, Emmelkamp PM, Essau CA, Fava GA, Goschke T, Hermans D, Hofmann SG, Lutz W, Muris P, Ollendick TH, Raes F, Rief W, Riper H, Tossani E, van der Oord S, Vervliet B, Haro JM, Schumann G. Roadmap for Mental Health Research in Europe (Roamer) The need for a behavioural science focus in research in mental health and mental disorders. *Int J Methods Psychiatr Res.*; 23 Suppl 1:28-40. doi: 10.1002/mpr.1409, Jan 2014.
316. Belaise C, Gatti A, Chouinard VA, Chouinard G: Persistent Postwithdrawal Disorders Induced by Paroxetine, a Selective Serotonin Reuptake Inhibitor (SSRI), and Treated by Specific Cognitive Behavioral Therapy (CBT). *Psychother Psychosom* 83: 247-248, 2014.
316. Chouinard G, Chouinard VA: New Classification of Selective Serotonin Reuptake Inhibitor Withdrawal. *Psychother Psychosom* 2015; 84: 63-71.

Guy Chouinard

April 16, 2015